Esperion Therapeutics (ESPR)

• Market cap: $453M
• 1 day: 2.68%
• 5 days: -4.17%
• 1 month: -10.51%
• 3 months: 39.39%
• 6 months: 5.50%
• Year to date: -21.23%
• 1 year: -10.85%
• 5 years: -95.98%
• 10 years: -93.61%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Employees: 240

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

41% more call options, than puts

Call options by funds: $3.08M | Put options by funds: $2.19M

29% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 24

11% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 44

4% more funds holding

Funds holding: 175 [Q2] → 182 (+7) [Q3]

5.71% less ownership

Funds ownership: 73.94% [Q2] → 68.23% (-5.71%) [Q3]

31% less capital invested

Capital invested by funds: $311M [Q2] → $214M (-$97.1M) [Q3]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 74% upside
• Avg. target: $8.50 270% upside
• High target: $16 596% upside

4 analyst ratings

• positive: 3 75%
• neutral: 1 25%
• negative: 0 0%

Goldman Sachs Paul Choi 30% 1-year accuracy 3 / 10 met price target	74% upside $4	Neutral Reinstated	18 Dec 2024
Cantor Fitzgerald Kristen Kluska 38% 1-year accuracy 40 / 105 met price target	248% upside $8	Overweight Initiated	17 Dec 2024
Needham Serge Belanger 37% 1-year accuracy 47 / 126 met price target	161% upside $6	Buy Reiterated	13 Dec 2024
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 82 / 386 met price target	596% upside $16	Buy Reiterated	13 Dec 2024